{"prompt": "['INVESTIGATOR SIGNATURE PAGE', 'Study Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center', 'Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the', 'Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or', 'Bipolar Il Disorder (Bipolar Depression) Conducted Globally', 'Protocol Number: ITI-007-404', 'The signature below constitutes the approval of this protocol and the attachments, and', 'provides the necessary assurances that this trial will be conducted according to all', 'stipulations of the protocol, including all statements regarding confidentiality, and', 'according to local legal and regulatory requirements and applicable US federal and/or', 'local regulations and ICH guidelines.', 'I will not supply the investigational drug to any person not authorized to receive it.', 'Confidentiality will be protected. Patient identity will not be disclosed to third parties or', 'appear in any study reports or publications.', 'I will not disclose information regarding this clinical investigation or publish results of the', 'investigation without prior authorization from ITI.', 'Principal Investigator or Clinical Study Site Investigator:', 'Signed:', 'Date:', 'Name:', 'Title:', 'Intra-Cellular Therapies, Inc. Confidential', 'iii ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['TABLE OF CONTENTS', 'PAGE', 'STATEMENT OF COMPLIANCE', 'I', 'INVESTIGATOR SIGNATURE PAGE', 'III', 'TABLE OF CONTENTS', 'IV', 'LIST OF ABBREVIATIONS', 'VIII', 'PROTOCOL SUMMARY', 'XI', '1', 'KEY ROLES AND CONTACT INFORMATION', '1', '2', 'INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE', '2', '2.1', 'Background Information', '2', '2.2', 'Rationale', '4', '2.3', 'Potential Risks and Benefits', '5', '2.3.1', 'Potential Risks', '5', '2.3.2', 'Potential Benefits', '7', '3', 'OBJECTIVES', '8', '3.1', 'Study Objectives', '8', '3.2', 'Study Outcome Measures', '10', '3.2.1 Primary', '10', '3.2.2 Secondary', '10', '4', 'STUDY DESIGN', '11', '5', 'STUDY ENROLLMENT AND WITHDRAWAL', '12', '5.1', 'Patient Inclusion Criteria', '12', '5.2', 'Patient Exclusion Criteria', '13', '5.3', 'Strategies for Recruitment and Retention', '18', '5.4', 'Treatment Assignment Procedures', '18', '5.4.1', 'Randomization Procedures', '18', '5.4.2', 'Masking Procedures', '19', '5.4.3', 'Breaking the Blind', '19', '5.5', 'Patient Withdrawal', '19', '5.5.1', 'Reasons for Withdrawal', '20', '5.5.2 Handling of Patient Withdrawals or Patient Discontinuation of Study', 'Intervention', '21', '5.6', 'Premature Termination or Suspension of Study', '21', '6', 'STUDY INTERVENTION', '22', '6.1', 'Study Product Description', '22', '6.1.1', 'Acquisition', '24', '6.1.2 Formulation, Packaging, and Labeling', '24', '6.1.3 Product Storage and Stability', '24', '6.2', 'Dosage, Preparation and Administration of Study Product', '25', '6.3', 'Modification of Study Product Administration for a Patient', '25', '6.4', 'Accountability Procedures for the Study Product', '26', '6.5', 'Assessment of Patient Compliance with Study Product Administration', '26', '6.6', 'Concomitant Medications/Treatments', '26', 'Intra-Cellular Therapies, Inc. Confidential', 'iv ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['7', 'STUDY SCHEDULE', '28', '7.1', 'Screening (Visit 1)', '28', '7.2', 'Enrollment/Baseline (Visit 2, Day 1)', '29', '7.3', 'Visit 3, Day 8 1', '29', '7.4', 'Visit 4, Day 15 1', '30', '7.5', 'Visit 5, Day 22 + 1', '30', '7.6', 'Visit 6, Day 29 1', '30', '7.7', 'Visit 7, Day 36 + 1', '31', '7.8', 'Visit 8, Day 43 + 1', '31', '7.9', 'Follow-up (Visit 9, Day 57 2)', '31', '7.10', 'Early Discontinuation Visit (Visit 10, if needed)', '32', '8', 'STUDY PROCEDURES /EVALUATIONS', '33', '8.1', 'Study Procedures/Evaluations', '33', '8.1.1', 'Informed Consent', '33', '8.1.2', 'Medical History and Other Information', '33', '8.1.3', 'Modified Physical Examination', '33', '8.1.4', 'Electrocardiogram Assessments', '34', '8.1.5', 'Vital Sign Measurements', '34', '8.1.6 Mini International Neuropsychiatric Interview', '35', '8.1.7', 'Columbia Suicide Severity Rating Scale', '35', '8.1.8', 'Young Mania Rating Scale', '35', '8.1.9', 'Clinical Global Impressions of Severity', '36', '8.1.10 Eligibility Adjudication', '36', '8.2', 'Efficacy Assessments and Procedures', '36', '8.2.1', 'MADRS', '36', '8.2.2', 'Clinical Global Impression of Severity', '37', '8.2.3', 'Q-LES-Q-SF', '37', '8.3', 'Patient Placebo Questionnaire and Training:', '37', '8.4', 'Safety and Tolerability Assessments', '37', '8.5', 'Laboratory Procedures/Evaluations', '37', '8.5.1', 'Clinical Laboratory Evaluations', '37', '8.5.2', 'Hepatitis Screening', '39', '8.5.3', 'HIV Screening', '39', '8.5.4', 'Urine Drug and Alcohol Screening', '39', '8.5.5', 'Laboratory Assessments', '40', '8.5.6', 'Urine and Serum Pregnancy Test', '40', '8.5.7 Frequency and Volume of Blood Collection', '40', '8.5.8', 'Special Assays or Procedures', '41', '8.6', 'Pharmacokinetic Assessments', '41', '8.6.1 Specimen Preparation, Handling, and Storage', '41', '8.6.2 Specimen Shipment', '41', '9', 'ASSESSMENT OF SAFETY', '42', '9.1', 'Specification of Safety Parameters', '42', '9.1.1 C-SSRS', '42', 'Intra-Cellular Therapies, Inc. Confidential', 'V ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}